Results 71 to 80 of about 25,852 (227)

Isolated Limb Perfusion for In-Transit Melanoma Metastases: Melphalan or TNF-Melphalan Perfusion?

, 2014
Indications for treatment of melanoma in-transit metastases (ITMs) confined to the limb with isolated limb perfusion (ILP) are not well defined. This study reports the Groningen regional therapeutic perfusion experience with melphalan (M-ILP) and TNF ...
Van Ginkel, Robert J., Hoekstra, Harald J., Veerman, Kelly   +2 more
core   +1 more source

Transplantation outcomes in patients with Down syndrome‐associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies

British Journal of Haematology, EarlyView.
This nationwide study of 56 patients with Down syndrome‐associated acute lymphoblastic leukaemia (ALL) demonstrated that haematopoietic stem cell transplantation (HSCT) in complete remission (CR)1/2 yields comparable event‐free survival to non‐Down syndrome ALL.
Hisashi Ishida, Yasuhiro Okamoto, Hirotoshi Sakaguchi, Yasuyuki Arai, Tomoaki Ueda, Shunsuke Yamamoto, Mio Yano, Tomoko Yokosuka, Keiko Okada, Maho Sato, Shuhei Karakawa, Ryoji Kobayashi, Keisuke Kato, Katsuyoshi Koh, Toshihiro Fujiki, Kumiko Goi, Shoji Saito, Junko Takita, Takako Miyamura, Yuhki Koga, Nao Yoshida, Atsushi Sato, Moeko Hino, Ken Tabuchi, Yuki Arakawa   +24 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape. [PDF]

Eur J Haematol
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
Mancuso K, Masci S, Talarico M, Vitale A, Barbato S, Solli V, Puppi M, Rizzello I, Pantani L, Tacchetti P, Iezza M, Restuccia R, Sacchetti I, Manzato E, Ghibellini S, Armuzzi S, Taurisano B, Cavo M, Zamagni E.   +18 more
europepmc   +2 more sources

Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution

, 2013
Sheila Thampi,1 Steven W Hetts,3 Daniel L Cooke,3 Paul J Stewart,2 Elizabeth Robbins,1 Anuradha Banerjee,1 Steven G DuBois,1 Devron Char,2 Van Halbach,3 Katherine Matthay11Department of Pediatrics, 2Department of Ophthalmology, 3Department of Radiology ...
Robbins E, DuBois SG, Matthay K, Cooke DL, Char D, Thampi S, Stewart PJ, Hetts SW, Banerjee A, Halbach V   +9 more
core  

Pharmacokinetics of Melphalan after Intravitreal Injection in a Rabbit Model [PDF]

, 2016
Purpose: Although widely used for vitreous seed control in retinoblastoma patients, currently there are no data on melphalan pharmacokinetics after intravitreal injections. Therefore, in this study, we characterized the ocular and systemic disposition of
Winter, Ursula Andrea, Schaiquevich, Paula Susana, Williams, Gustavo, Asprea, Marcelo, Buitrago, Emiliano, Chantada, Guillermo Luis   +5 more
core   +1 more source

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells

, 2015
Melphalan represents the reference drug for locoregional chemotherapy of melanoma; nevertheless, treatment failure may occur because of resistance to chemotherapy.
De Terlizzi, Francesca, Luca Giovanni Campana, ROSSI, CARLO RICCARDO, Carlo Riccardo Rossi, CAMPANA, LUCA GIOVANNI, De Mattei, Monica, Pellati, Agnese, Francesca De Terlizzi, ONGARO, ALESSIA   +8 more
core   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Autopsy analysis may contribute to establish actual incidence of second primary malignancies in myeloma

Rare Tumors, 2015
Second primary malignancies (SPMs) are issues for patients with multiple myeloma (MM). There may have been some limitations in prior studies, such as difficulties in a longer follow-up and absence of established screening methods.
Junichiro Takano, Shotaro Hagiwara, Akiyoshi Miwa   +2 more
doaj   +1 more source

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

European Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V. Glavey, Ann M. Hopkins   +10 more
wiley   +1 more source